IMPACT Therapeutics Taps Pharmanovia for Global Senaparib Expansion

The agreement covers maintenance monotherapy for advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer. Pharmanovia will handle manufacturing, development, and commercialization across the European Union, the United Kingdom, Switzerland, Australia, New Zealand, and regions in the Middle East and North Africa. In exchange, IMPACT stands to collect an upfront payment, regulatory and commercial milestone fees, and tiered royalties reaching the mid-twenties percentage range on net sales.

This expansion arrives as the drug gains regulatory momentum. The European Medicines Agency formally accepted the marketing authorization application for senaparib as a first-line maintenance therapy in August 2025, with a final decision expected in the second half of 2026. For IMPACT, which debuted on the Hong Kong Stock Exchange in May 2026, the collaboration serves as a vehicle to leverage Pharmanovia’s established infrastructure to accelerate patient access. Senaparib, a PARP1/2 inhibitor, remains the company’s core asset, having secured approval and national reimbursement status in China throughout 2025.